Loading...

We've got a brand new version of Simply Wall St! Try it out

Ovation Science

CNSX:OVAT
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OVAT
CNSX
CA$7M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Ovation Science Inc. engages in sublicensing the Invisicare technology to licensed businesses engaged in the production of cannabis or hemp seed oil products in Canada. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
OVAT Share Price and Events
7 Day Returns
20.8%
CNSX:OVAT
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:OVAT
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
OVAT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ovation Science (OVAT) 20.8% 3.2% -33.3% - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on OVAT.
  • No trading data on OVAT.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Ovation Science undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ovation Science. This is due to cash flow or dividend data being unavailable. The share price is CA$0.32.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ovation Science's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ovation Science's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:OVAT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.03
CNSX:OVAT Share Price ** CNSX (2019-09-19) in CAD CA$0.32
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ovation Science.

CNSX:OVAT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:OVAT Share Price ÷ EPS (both in CAD)

= 0.32 ÷ -0.03

-9.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ovation Science is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Ovation Science is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Ovation Science's expected growth come at a high price?
Raw Data
CNSX:OVAT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ovation Science, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ovation Science's assets?
Raw Data
CNSX:OVAT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.08
CNSX:OVAT Share Price * CNSX (2019-09-19) in CAD CA$0.32
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:OVAT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:OVAT Share Price ÷ Book Value per Share (both in CAD)

= 0.32 ÷ 0.08

4.05x

* Primary Listing of Ovation Science.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ovation Science is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Ovation Science's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Ovation Science has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ovation Science expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ovation Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ovation Science expected to grow at an attractive rate?
  • Unable to compare Ovation Science's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Ovation Science's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Ovation Science's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:OVAT Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:OVAT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:OVAT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -1 -1
2019-03-31 0 0 -1
2018-12-31 0 0 -1
2017-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Ovation Science is high growth as no earnings estimate data is available.
  • Unable to determine if Ovation Science is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:OVAT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ovation Science Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:OVAT Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.03
2019-03-31 -0.03
2018-12-31 -0.03
2017-12-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ovation Science will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Ovation Science's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Ovation Science's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Ovation Science's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Ovation Science's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ovation Science has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ovation Science performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ovation Science's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ovation Science does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Ovation Science's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ovation Science's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Ovation Science's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ovation Science Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:OVAT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.19 -0.68 0.66 0.09
2019-03-31 0.16 -0.61 0.54 0.08
2018-12-31 0.10 -0.51 0.43 0.06
2017-12-31 0.03 -0.15 0.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ovation Science has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ovation Science has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ovation Science improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ovation Science's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ovation Science has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ovation Science's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ovation Science's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ovation Science is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ovation Science has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ovation Science's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ovation Science Company Filings, last reported 2 months ago.

CNSX:OVAT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1.84 0.28 1.50
2019-03-31 2.02 0.28 1.72
2018-12-31 2.19 0.28 1.97
2017-12-31 0.57 0.30 0.28
  • Ovation Science's level of debt (15.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Ovation Science's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ovation Science has sufficient cash runway for 2.5 years based on current free cash flow.
  • Ovation Science has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -45.5% each year.
X
Financial health checks
We assess Ovation Science's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ovation Science has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ovation Science's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ovation Science dividends.
If you bought CA$2,000 of Ovation Science shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ovation Science's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ovation Science's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:OVAT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ovation Science has not reported any payouts.
  • Unable to verify if Ovation Science's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ovation Science's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ovation Science has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ovation Science's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ovation Science afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ovation Science has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ovation Science's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Terry Howlett
COMPENSATION CA$74,942
AGE 71
TENURE AS CEO 1.9 years
CEO Bio

Mr. Terry H. Howlett has been the Chief Executive Officer and President of Skinvisible Inc. since March 5, 1998 and serves as its Chief Financial Officer, Treasurer and Secretary. Mr. Howlett serves as the President, Treasurer and Secretary of Skinvisible Pharmaceuticals Inc., Safe4Hours Inc. and Skinvisible Pharmaceuticals (Canada) Inc., subsidiaries of Skinvisible Inc. Mr. Howlett founded Presley Laboratories, Inc. He served as the Chief Executive Officer and President of Voice-it Solutions, Inc. He has a diversified background in market initialization and development, sales and venture capital financing for emerging growth companies. He held senior management, marketing and sales positions with various companies, including: Canadian Federation of Independent Business, Family Life Insurance and Avacare of Canada. He has been a Director of Skinvisible Inc., since March 5, 1998 and serves as Director of Safe4Hours Inc., Skinvisible Pharmaceuticals (Canada) Inc. and Skinvisible Pharmaceuticals Inc. Mr. Howlett serves as Chief Executive Officer and Director at Ovation Science Inc. since October 4, 2017 and also serves as its President.

CEO Compensation
  • Terry's compensation has increased whilst company is loss making.
  • Terry's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Ovation Science management team in years:

1.9
Average Tenure
60.5
Average Age
  • The average tenure for the Ovation Science management team is less than 2 years, this suggests a new team.
Management Team

Terry Howlett

TITLE
President
COMPENSATION
CA$75K
AGE
71
TENURE
1.9 yrs

Logan Anderson

TITLE
CFO, Secretary & Director
COMPENSATION
CA$47K
AGE
64
TENURE
1.9 yrs

Doreen McMorran

TITLE
VP, COO & Director
COMPENSATION
CA$51K
AGE
57
TENURE
0.8 yrs

Dave Ryan

TITLE
Head of Investor Relations & Director
COMPENSATION
CA$43K
AGE
52
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Ovation Science board of directors in years:

1.9
Average Tenure
60.5
Average Age
  • The average tenure for the Ovation Science board of directors is less than 3 years, this suggests a new board.
Board of Directors

Terry Howlett

TITLE
President
COMPENSATION
CA$75K
AGE
71
TENURE
1.9 yrs

Logan Anderson

TITLE
CFO, Secretary & Director
COMPENSATION
CA$47K
AGE
64
TENURE
2.2 yrs

Doreen McMorran

TITLE
VP, COO & Director
COMPENSATION
CA$51K
AGE
57
TENURE
1.9 yrs

Dave Ryan

TITLE
Head of Investor Relations & Director
COMPENSATION
CA$43K
AGE
52
TENURE
1.9 yrs

Ian Howard

TITLE
Director
COMPENSATION
CA$2K
TENURE
1.6 yrs

Joan Chypyha

TITLE
Director
COMPENSATION
CA$2K
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Ovation Science individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
19. Aug 19 Buy David Ryan Individual 15. Aug 19 15. Aug 19 10,000 CA$0.32 CA$3,190
12. Aug 19 Buy David Ryan Individual 12. Aug 19 12. Aug 19 3,000 CA$0.25 CA$750
29. Nov 18 Buy David Ryan Individual 28. Nov 18 28. Nov 18 5,500 CA$0.30 CA$1,645
X
Management checks
We assess Ovation Science's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ovation Science has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could Ovation Science Inc.'s (CNSX:OVAT) Investor Composition Influence The Stock Price?

Ovation Science is a smaller company with a market capitalization of CA$9.3m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for Ovation Science CNSX:OVAT Ownership Summary, July 30th 2019 What Does The Lack Of Institutional Ownership Tell Us About Ovation Science? … General Public Ownership The general public -- mostly retail investors -- own 64% of Ovation Science.

Simply Wall St -

What Does Ovation Science Inc.'s (CNSX:OVAT) Balance Sheet Tell Us About It?

(CNSX:OVAT) with its market cap of CA$14m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Company Info

Description

Ovation Science Inc. engages in sublicensing the Invisicare technology to licensed businesses engaged in the production of cannabis or hemp seed oil products in Canada. The company’s Invisicare is a patented drug delivery technology used in topical and transdermal skin products containing hemp seed oil and cannabis products. It holds sublicenses for cannabis based products in Canada and in the United States; and Lighthouse for licensed dispensaries in the United States. The company was founded in 2017 and is headquartered in Vancouver, Canada.

Details
Name: Ovation Science Inc.
OVAT
Exchange: CNSX
Founded: 2017
CA$7,431,881
23,224,631
Website: http://ovationscience.com
Address: Ovation Science Inc.
744 West Hastings Street,
Suite 510,
Vancouver,
British Columbia, V6C 1A5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX OVAT Common Shares Canadian National Stock Exchange CA CAD 15. Nov 2018
OTCPK OVAT.F Common Shares Pink Sheets LLC US USD 15. Nov 2018
Number of employees
Current staff
Staff numbers
0
Ovation Science employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:35
End of day share price update: 2019/09/19 00:00
Last earnings filing: 2019/08/28
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.